The effect of low-dose methotrexate on bone mineral density in patients with early rheumatoid arthritis
- First Online:
- 130 Downloads
The intent of this study was to assess the effect of low-dose methotrexate treatment on bone mineral density (BMD) in patients with early rheumatoid arthritis (RA).
Forty-six premenopausal women with early RA not previously treated with disease-modifying antirheumatic drugs or corticosteroid were randomized to 7.5 mg/week of methotrexate or 2 g/day of sulphasalazine for 18 months. Bone mineral density of the lumbar spine, femoral neck, and trochanter was measured using dual-energy X-ray absorptiometry (DEXA). Biochemical studies included serum calcium, phosphorus, total alkaline phosphatase, beta-2 microglobulin, parathyroid hormone and 25-hydroxyvitamin D3 concentrations, spot urinary calcium, and 24-h urinary calcium excretion. Disease activity was assessed by modified disease activity score (DAS 28), and functional impairment was estimated by the Health Assessment Questionnaire.
No significant difference in BMD of the lumbar spine, femur neck, or trochanter was observed at 18 months in either group. There was also no significant change in the biochemical parameters of both groups.
Our findings suggest that low-dose methotrexate has no negative effect on BMD in premenopausal RA patients.
KeywordsMethotrexate Osteoporosis Rheumatoid arthritis Sulphasalazine
- 3.Prevoo MLL, Van Gestel AM, Van t'Hof MA, Van Rijswýjk MH, Van De Putte LBA, Van Riel PLCM (1996) Remission in a prospective study of patients with rheumatoid arthritis. American Rheumatism Association preliminary remission criteria in relation to the disease activity score. Br J Rheumatol 35:1101–1105CrossRefPubMedGoogle Scholar
- 5.Dequeker J, Maenaut K, Verwilghen J, Westhowens R (1995) Osteoporosis in rheumatoid arthritis. Clin Exp Rheumatol 13 [Suppl 12]:S1–S6Google Scholar
- 6.Suzuki Y, Mizushima Y (1997) Osteoporosis in rheumatoid arthritis. Osteoporos Int 7 [Suppl 3]:S217–S222Google Scholar
- 13.Eastgate JA, Wood NC, Di Giovine FS, Symons JA, Grinlinton FM, Duff GW (1988) Correlation of plasma interleukin-1 levels with disease activity in rheumatoid arthritis. Lancet 340:706–709Google Scholar
- 27.Blum M, Wallenstein CJ, Luckey M (1996) Effect of methotrexate on bone in postmenopausal women with primary biliary cirrhosis. J Bone Miner Res 11:T545Google Scholar
- 29.Buckley LM, Leib ES, Cartularo KS, Vacek PM, Cooper SM (1997) Effects of low dose methotrexate on bone mineral density of patients with rheumatoid arthritis. J Rheumatol 29 1489–1494Google Scholar
- 32.Prevoo MLL, Van t'Hof MA, Kuper HH, van Leeuwen MA, van de Putte LBA, van Riel PLCM (1995) Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38:44–48PubMedGoogle Scholar
- 34.Buchbinder R, Hall S, Sambrook PN, Champion GD, Harkness A, Lewis D, Littlejohn GO, Miller MH, Ryan PF (1993) Methotrexate therapy in rheumatoid arthritis: a life table review of 587 patients treated in community practice. J Rheumatol 20:639–644Google Scholar
- 36.Sinigaglia L, Nervetti A, Mela Q, Bianchi G, Del Puente A, Di Munno O, Frediani B, Cantatore F, Pellerito R, Bartolone S, La Montagna G, Adami S (2000) A multicenter cross sectional study on bone mineral density in rheumatoid arthritis. Italian Study Group on bone mass in rheumatoid arthritis. J Rheumatol 27:2582–2589PubMedGoogle Scholar
- 40.Moe SM, Sprague SM (1992) Beta2-microglobulin induces calcium efflux from cultured neonatal mouse calvaria. Am J Physiol 263:540–545Google Scholar